Cancer

Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor volume and increased survival compared with either antibody or an a single, isotype-matched control. Next steps could include testing CD40 agonists and CSF1R inhibitors in other mouse models of colorectal cancer.

Memgen LLC has ISF35, an immunostimulatory CD40 binding protein, in Phase II testing for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). ...